Page 2 - Nasdaq Cmpx News Today

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,190,000 shares, an increase of 5.3% from the April 15th total of 2,080,000 shares. Based on an average daily trading volume, of 364,900 shares, the days-to-cover ratio […]

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last […]

Compass Therapeutics (NASDAQ:CMPX – Get Rating) and BioAtla (NASDAQ:BCAB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Valuation & Earnings This table compares Compass Therapeutics and BioAtla’s […]

Compass Therapeutics (NASDAQ:CMPX – Get Rating) and Valneva (NASDAQ:VALN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Institutional and Insider Ownership 54.3% of Compass Therapeutics shares are […]

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 2,130,000 shares, an increase of 17.7% from the February 28th total of 1,810,000 shares. Based on an average daily trading volume, of 376,700 shares, the days-to-cover ratio is currently 5.7 […]

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz acquired 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The shares were bought at an average price of $2.80 per share, with a total value of $56,000.00. Following the completion of the transaction, the chief executive officer […]

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 157,100 shares, a decrease of 32.1% from the May 15th total of 231,400 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average […]

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz bought 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average price of $2.29 per share, with a total value of $68,700.00. Following the transaction, the chief executive officer now directly owns […]

Small-cap stocks are usually young companies that present significant growth potential, but they are less stable than large-cap stocks. However, a com

Equities analysts expect that Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) will announce earnings per share (EPS) of ($0.09) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Compass Therapeutics’ earnings, with estimates ranging from ($0.14) to ($0.06). The firm is expected to report its next earnings report on Monday, […]